Article
A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors.
Proceedings of the National Academy of Sciences of the United States of America - 3 May 2022
Feng Siyu, Callow Marinella G, Fortin Jean-Philippe, Khan Zia, Bray David, Costa Mike, Shi Zhen, Wang Weiru, Evangelista Marie
Abstract excerpt
Mutant-specific inhibitors of KRASG12C, such as AMG510 (sotorasib) and MRTX849 (adagrasib), offer the unprecedented opportunity to inhibit KRAS, the most frequently mutated and heretofore undruggable oncoprotein. While clinical data are still limited, on-target mutations in KRASG12C at position 12 and other sites are emerging as major drivers of clinical relapse. We identified additional mutations in KRASG12C...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.